Editing AUA: Upper Tract Urothelial Carcinoma (2023) (section)

==== Repeat endoscopic evaluation ====
*'''<span style="color:#ff0000">Should be performed within 3 months</span>'''
**Proclivity of UTUC to recur and for residual disease to remain after the first ablation
**A 30-day window on either side of this endpoint (i.e., 30 to 90 days) is justified to allow timely identification of recurrences and may be dictated by aspects such as tumor size, visualization, access, treatment efficacy, etc., as clinically indicated
**'''<span style="color:#ff0000">If residual disease identified, repeat endoscopic assessment should occur within 3-month intervals until no evidence of upper tract disease is identified.</span>'''
* '''In patients with LR UTUC with evidence of risk group progression (tumor size, focality, or grade) or when tumor ablation is not feasible,''' further endoscopic-assisted attempts are not recommended. '''surgical resection of all involved sites either by RNU or segmental resection of the ureter should be offered.'''